▲ S&P 500 +---% | ▲ Stock Advisor +---% Join The Motley Fool

Accessibility Log In Help

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Brian Orelli, PhD

TMFBiologyFool

Dr. Orelli is a Senior Biotech Specialist. He has written about biotech, pharmaceutical, and medical device companies for The Motley Fool since 2007.

Recent Articles by Brian Orelli, PhD

Upgrade

Aug 31, 2017 by Brian Orelli, PhD

Why bluebird bio Inc Continued Its March Higher Again Today

Analyst upgrades add fuel to the fire.

Cells

Aug 30, 2017 by Brian Orelli, PhD

Why bluebird bio Inc Jumped Higher Today

FDA approval of Novartis' CAR-T therapy bodes well for the biotech, even if it was widely expected.

Doctor Patient 2

Aug 29, 2017 by Brian Orelli, PhD

Why Abeona Therapeutics Inc. (and Maybe Sangamo Therapeutics, Inc.) Jumped Higher Today

An FDA "breakthrough therapy" designation for Abeona's gene therapy sent shares of the company higher, but investors should focus on the bigger picture.

Leukemia cells

Aug 29, 2017 by Brian Orelli, PhD

Why ImmunoGen, Inc. Jumped Higher Today

A deal with Jazz Pharmaceuticals has investors dancing the Lindy hop.

Leukemia cells

Aug 28, 2017 by Brian Orelli, PhD

Why bluebird bio Inc and Juno Therapeutics Inc Shot Higher Today

The biotechs' surge is related to a big move for fellow immuno-oncology drug developer Kite Pharma.

Parkinsons disease

Aug 25, 2017 by Brian Orelli, PhD

Why Adamas Pharmaceuticals Inc Stock Skyrocketed Today

FDA approvals tend to make investors happy.

Production-NovoRapid-Hilleroed-hires[1]

Aug 14, 2017 by Brian Orelli, PhD

Novo Nordisk A/S Continues Its Comeback

A solid-enough second quarter from the diabetes specialist boosts investors' confidence in a turnaround.

Doctor Patient 2

Aug 14, 2017 by Brian Orelli, PhD

Alnylam Pharmaceuticals, Inc. Earnings: Waiting for Apollo

Next month's phase 3 data are much more important than the biotech's second-quarter earnings release.

Doctor Patient 2

Aug 11, 2017 by Brian Orelli, PhD

Ionis Pharmaceuticals Inc: Growing Royalties, an Advancing Pipeline, and Getting Back Rights to Some Drugs

A solid second quarter from the biotech, with growing royalties on Spinraza and two more drugs to be reviewed by regulators, and it regained full rights to two drugs after its partner declined to license them.

Increasing drug sales

Aug 10, 2017 by Brian Orelli, PhD

Why Impax Laboratories Inc Is Up for a Second Straight Day

Analysts upped their price targets following a solid second-quarter report from the drugmaker.

Infusion

Aug 10, 2017 by Brian Orelli, PhD

Diplomat Pharmacy Inc Makes Up for Lost Contracts

After losing some contracts, the specialty pharmacy company has been able to replace that revenue, setting itself up for growth next year.

Money Pills

Aug 9, 2017 by Brian Orelli, PhD

Why Impax Laboratories Inc Jumped Higher Today

A solid second quarter from the drugmaker.

Blood sample

Aug 9, 2017 by Brian Orelli, PhD

Becton Dickinson and Co Faces a Rough Comparator

On an adjusted basis, the medical and science supply company is doing fine.

Doctor Chest X-ray

Aug 8, 2017 by Brian Orelli, PhD

Why FibroGen Inc Skyrocketed Higher Today

Positive phase 2 data for the company's lung drug increases the biotech's value.

Anthrax blood vial

Aug 7, 2017 by Brian Orelli, PhD

Emergent Biosolutions Inc Diversifies Its Revenue

Three newly acquired products.

Sickle red blood cells

Aug 7, 2017 by Brian Orelli, PhD

bluebird bio Pauses During 2017 Data Blitz

With the ASCO and EHA conferences behind it, the biotech looks to ASH to end the year with a bang.

Scientist in lab

Aug 4, 2017 by Brian Orelli, PhD

Exelixis, Inc. Grows Revenue, Eyes Treating More Patients

Cabometyx is still in hypergrowth, and approvals for additional indications could be here shortly.

Pills

Aug 4, 2017 by Brian Orelli, PhD

Why Teva Pharmaceutical Industries Stock Fell for a Second Straight Day

Analyst downgrades are sinking shares of the generic-drug maker.

Aug 4, 2017 by Brian Orelli, PhD

BioMarin Pharmaceutical Inc. Got It Done in the Second Quarter

The biotech produced growing drug sales, won an FDA and EMA approval, filed a marketing application for another drug, and released promising on data on pipeline candidates.

Money Pills

Aug 3, 2017 by Brian Orelli, PhD

Why AmerisourceBergen Corp. Fell Dramatically Today

The drug distributor sees pressure on drug prices.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services